Drugs / gp96
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02122822 | Jul 2013 → Jul 2015 | glioma | Cure&Sure Biotech Co., LTD | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02317471 | Nov 2014 → Dec 2017 | gastric carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02133079 | Mar 2012 → Nov 2016 | liver cancer, pancreatic adenocarcinoma | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03650257 | Aug 2019 → Aug 2021 | brain glioma | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04206254 | Dec 2019 → Aug 2022 | liver cancer | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp96 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02133079 ↗ |
| Known as | heat shock protein gp96 | “Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96” NCT02133079 ↗ |
| Action | Deplete | “may help the body build an effective immune response to kill tumor cells.” NCT04206254 ↗ |
| Modality | Vaccine | “autologous gp96 vaccination” NCT02133079 ↗ |
| Route | Subcutaneous | “gp96 of 25ug in 1mL normal saline s.c.” NCT02317471 ↗ |